Clever Culture Systems’ (ASX: CC5) March quarter delivered exactly what investors look for: execution, diversification and momentum. The company has placed nine APAS® Independence instruments year‑to‑date, reaffirming guidance of at least 11 placements for FY26, matching FY25 but with a far healthier customer spread. Last year, AstraZeneca accounted for 80% of sales; this year CCS has added global names including Novo Nordisk, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer and Thermo Fisher, signaling that its strategy to broaden the customer base is working. As the quarterly report states, “FY26 is focused on expanding the quality and breadth of our customer base by engaging with leading global pharmaceutical manufacturers.”
The company is now in advanced contracting with two new top‑20 pharma customers, expected to close within FY26. The installed base has grown to 30 instruments, with two more under evaluation, and AstraZeneca’s APAS® program was recognised globally with the Professor Wallhäußer 2026 Award, reinforcing the platform’s credibility in GMP environments.
Financially, CCS remains steady with $2 million in cash and $2.6 million in committed inflows expected over the next two quarters, including AstraZeneca installations, new pharma contracts and the FY26 R&D tax incentive. With a broader customer base and major deals nearing completion, CCS is positioning FY26 as a foundation year that sets up a stronger, more scalable FY27. Click here to download quarterly report.
